A Phase 0/I, Open Label, Single Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Myrcludex B in Healthy Volunteers

Trial Profile

A Phase 0/I, Open Label, Single Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Myrcludex B in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Myrcludex-B (Primary) ; Myrcludex-B (Primary)
  • Indications Hepatitis B; Hepatitis D
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 01 Jun 2016 Results of this trial have been published in the Journal of Hepatology, according to a Hepatera media release.
    • 05 May 2016 New trial record
    • 27 Apr 2016 Results published in the Journal of Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top